<?xml version="1.0" encoding="UTF-8"?>
<p>The second vaccine licensed for ZVL was Leishtec®, which is composed of the recombinant protein A2 of amastigotes of 
 <italic>L</italic>. (L.) 
 <italic>donovani</italic> and saponin. A2 is an important virulence factor, preferentially expressed in amastigotes, that is involved in resistance in the visceral organs and in resistance against stress (
 <xref rid="B115" ref-type="bibr">115</xref>, 
 <xref rid="B116" ref-type="bibr">116</xref>). A2 was shown to be protective against VL in mice (
 <xref rid="B117" ref-type="bibr">117</xref>–
 <xref rid="B119" ref-type="bibr">119</xref>), in non-human primate models (
 <xref rid="B120" ref-type="bibr">120</xref>), and in a kennel assay with beagle dogs (
 <xref rid="B85" ref-type="bibr">85</xref>).
</p>
